Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer

NCT07322094 is registered in ClinicalTrials.gov with TORL Biotherapeutics, LLC as lead sponsor.

NCT NCT07322094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07322094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CATALINA-4: Phase 1B/2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer
Lead sponsor
TORL Biotherapeutics, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 10, 2025
Completion date
January 31, 2028
Enrollment
60 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancers, figo stage iii and iv ovarian cancer, primary peritoneal cancer